- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
HIMA urges firms to use third-party review
The Health Industry Manufacturers Association is urging medical device companies to take increasing advantage of a third-party review system within the Food and Drug Administration to gain quicker approval for their products.Last month HIMA passed a
The Health Industry Manufacturers Association is urging medical device companies to take increasing advantage of a third-party review system within the Food and Drug Administration to gain quicker approval for their products.
Last month HIMA passed a resolution reminding companies to use the third-party review system. HIMA represents more than 800 manufacturers of medical devices, diagnostic products, and medical information systems.
The Food and Drug Administration Modernization Act, passed three years ago, devised the third-party system in response to a growing backlog of FDA applications and a dearth of personnel to complete the reviews. The act created a group of scientific and industry experts qualified to grant FDA approval for medical devices, said Linda Ruckel, HIMA spokeswoman.
HIMA members may be hesitant to use the third-party review system for product approval because they arent used to it, Ruckel said.
We believe its a good thing. A lot of times (members) will go for the old tried and true way rather than a new format, Ruckel said. We know its out there and we want to encourage (companies) to use it more.
Four Strategies to Address the Tipping Point in Radiology
January 17th 2025In order to flip the script on the impact of the radiology workforce shortage, radiology groups and practices need to make sound investments in technologies and leverage partnerships to mitigate gaps in coverage and maximize workflow efficiencies.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI-Based AI Enhance Risk Stratification in Prostate Cancer?
January 13th 2025Employing baseline MRI and clinical data, an emerging deep learning model was 32 percent more likely to predict the progression of low-risk prostate cancer (PCa) to clinically significant prostate cancer (csPCa), according to new research.
